Drug Profile
Research programme: antibacterial therapeutics - Asieris Pharmaceuticals
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Asieris Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Bacterial-infections in China
- 29 Aug 2017 Research programme: antibacterial therapeutics - Asieris Pharmaceuticals is available for licensing as of 29 Aug 2017. http://www.asieris.cn/index/
- 29 Aug 2017 Early research in Bacterial infections in China (unspecified route) (Asieris Pharmaceuticals website, August 2017)